Symphogen Announces the Appointment of Annika Espander Jansson
News Dec 23, 2013
Symphogen A/S has announced the appointment of Annika Espander Jansson as a Non-Executive Director of the Board, with effect from 19 December 2013.
Annika has over twenty years’ experience in the healthcare sector, both as a sell-side analyst and investor. She has a proven track record in strategic development of businesses and broad experience in managing operations in different segments of the financial markets.
Annika began her career as Equity Analyst and Sector Head of Healthcare at Aros Securities in Stockholm 1994-1996, followed by similar roles at Enskilda Securities, where she was Sector Head of Equity Research in Healthcare for five years, and Handelsbanken Capital Markets, where she gained experience of the financial services sector and became Group Head of Private Banking.
She joined Catella Healthcare, a private venture capital investor in healthcare companies, in 2004 as Managing Partner of a small team of professionals, during which time the IRR of the company’s portfolio exceeded 35%.
Annika returned to Handelsbanken as Global Head of Private Banking in September 2010-June 2013 during which time the bank’s ranking was upgraded to No. 1, according to the influential client survey - Prospera.
Annika is currently the founder and CEO of Asperia, a strategic and business advisory firm in the healthcare and financial services sectors. She is also a Board member of the public companies Stille AB and Probi AB, private portfolio companies Attana AB, Cellartis AB and Duocort AB, as well as the Swedish Financial Analyst Organization. Annika holds a Ph.D. from the University of Gothenburg.
Welcoming the appointment, Gôran Ando MD, Chairman of the Board, commented: “I am delighted to welcome Annika to Symphogen. Annika’s extensive experience in both the healthcare industry and financial markets makes her a perfect addition to the Board. Annika’s skills, knowledge and experience will be invaluable to furthering the success of Symphogen.”
Annika Espander Jansson added: “I am very excited to take part in the development of Symphogen which operates in a very important medical area with significant unmet medical needs and with a business concept aiming at improving therapies for cancer patients.”
Tight junctions are multi-protein complexes that serve as barriers in epithelial tissues such as the skin or lining of the gut. Loss of a specific tight junction barrier protein, claudin 18, occurs in the majority of gastric cancer patients and is correlated with poor prognosis in patients with advanced gastric cancer.READ MORE